Stock THAR THARIMMUNE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Tharimmune, Inc.

Equities

THAR

US4327053090

Market Closed - Nasdaq
Other stock markets
 21:00:00 21/06/2024 BST 		5-day change 1st Jan Change
2.82 USD -9.90% Intraday chart for Tharimmune, Inc. -15.82% -63.06%
06-20 Tharimmune Prices $2.1 Million Private Placement of Common Shares, Warrants MT
06-18 Tharimmune, Inc. announced that it expects to receive $2.084162 million in funding from GRAVITAS Capital Advisors, Inc., SDS Capital Group and other investors CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Tharimmune Prices $2.1 Million Private Placement of Common Shares, Warrants
MT
Tharimmune Announces Positive Type C Meeting with FDA for Phase 2 program for TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis
AQ
Tharimmune, Inc. announced that it expects to receive $2.084162 million in funding from GRAVITAS Capital Advisors, Inc., SDS Capital Group and other investors
CI
Tharimmune, Inc. Announces Positive Type C Meeting with FDA for Phase 2 Program for TH104, Its Lead Candidate for Moderate-To-Severe Pruritus in Primary Biliary Cholangitis
CI
Tharimmune, Inc. Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-To-Severe Pruritus in Primary Biliary Cholangitis
CI
Tharimmune to Present at 2024 BIO International Convention
AQ
Certain Warrants of Tharimmune, Inc. are subject to a Lock-Up Agreement Ending on 25-MAY-2024.
CI
Certain Options of Tharimmune, Inc. are subject to a Lock-Up Agreement Ending on 25-MAY-2024.
CI
Certain Common Stock of Tharimmune, Inc. are subject to a Lock-Up Agreement Ending on 25-MAY-2024.
CI
Tharimmune Announces 1-for-15 Reverse Stock Split
AQ
Tharimmune to Implement 1-for-15 Reverse Stock Split
MT
Tharimmune, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates
AQ
Tharimmune, Inc. Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates
CI
Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate Biotherapeutics
AQ
Tharimmune to Present at the Emerging Growth Conference on March 7, 2024
AQ
Tharimmune, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Tharimmune, Inc. Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate
CI
Tharimmune, Inc. Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis
CI
Tharimmune, Inc. Announces Initiation of Phase 1 Clinical Trial of TH104
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. THAR Stock
  4. News Tharimmune, Inc.